Neurogene (NASDAQ:NGNE) Insider Sells 6,797 Shares

Neurogene Inc. (NASDAQ:NGNE) insider Stuart Cobb sold 6,797 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the transaction, the insider owned 30,497 shares in the company, valued at approximately $634,642.57. This trade represents a 18.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Neurogene Stock Performance

NASDAQ:NGNE traded down $0.49 on Tuesday, hitting $21.08. The stock had a trading volume of 112,066 shares, compared to its average volume of 166,384. Neurogene Inc. has a 1 year low of $6.88 and a 1 year high of $37.27. The firm’s fifty day simple moving average is $19.11 and its two-hundred day simple moving average is $21.63. The stock has a market cap of $326.53 million, a P/E ratio of -5.13 and a beta of 1.53.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Lifesci Capital initiated coverage on Neurogene in a research report on Monday, January 26th. They issued an “outperform” rating and a $50.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Neurogene in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Neurogene currently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Hedge Funds Weigh In On Neurogene

Several institutional investors and hedge funds have recently bought and sold shares of the company. Schroder Investment Management Group purchased a new position in shares of Neurogene during the 2nd quarter valued at $451,000. Dimensional Fund Advisors LP purchased a new stake in Neurogene in the 4th quarter worth about $235,000. Wells Fargo & Company MN raised its stake in Neurogene by 45.2% in the 4th quarter. Wells Fargo & Company MN now owns 11,037 shares of the company’s stock valued at $227,000 after acquiring an additional 3,438 shares during the period. Brevan Howard Capital Management LP bought a new stake in Neurogene in the 3rd quarter valued at about $223,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Neurogene during the third quarter valued at about $187,000. 52.37% of the stock is owned by institutional investors.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.